GRPH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (22 Mar 2024 @ 04:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
今日成交量	299 406
平均成交量	40 955.00
市值	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.207
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

音量相关性

長: 0.15 (neutral)

短: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. 相关性

10 最正相关
RAM	0.943
FAAR	0.941
MTEK	0.936
PRIM	0.936
IXAQ	0.934
EVER	0.934
GHRS	0.933
JUPW	0.933
NVAC	0.931
SVFAU	0.931

10 最负相关
DYNT	-0.95
FTFT	-0.949
INFI	-0.939
HCDIP	-0.938
DGLY	-0.935
HFFG	-0.929
BMRC	-0.928
CGRN	-0.927
CMLS	-0.927
APPS	-0.926

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Graphite Bio, Inc. 相关性 - 货币/商品

-0.63
( weak negative )

-0.67
( moderate negative )

0.12
( neutral )

-0.69
( moderate negative )

0.44
( neutral )

Graphite Bio, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2023
营收:	$0
毛利润:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2022
营收:	$0
毛利润:	$-8.35M (0.00 %)
EPS:	$-1.760

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.